AJDRAJNR - American Journal of Neuroradiology

Published ahead of print on November 16, 2007
doi: 10.3174/ajnr.A0864

This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Google Scholar
Right arrow Articles by Massoud, T.F.
Right arrow Articles by Gambhir, S.S.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Massoud, T.F.
Right arrow Articles by Gambhir, S.S.

Noninvasive Molecular Neuroimaging Using Reporter Genes: Part I, Principles Revisited

T.F. Massouda,b, A. Singha and S.S. Gambhirb,c

a From the Department of Radiology, Section of Neuroradiology, University of Cambridge School of Clinical Medicine, Addenbrooke’s Hospital, Cambridge, UK
b Molecular Imaging Program at Stanford, Bio-X Program, Stanford University School of Medicine, Stanford, Calif
c Departments of Radiology and Bioengineering, Bio-X Program, Stanford University School of Medicine, Stanford, Calif


Figure 1
View larger version (29K):
[in this window]
[in a new window]

 
Fig 1. Reporter gene imaging. A, Schematic diagram of the principle of reporter gene imaging by using the enzyme firefly luciferase. Once the cell is transduced with a viral vector containing the imaging gene cassette, a promoter of choice drives the transcription of the imaging reporter gene (Fluc). If the promoter leads to transcription of Fluc, then translation of the imaging reporter gene mRNA leads to a protein product (the enzyme firefly luciferase) that can interact with the imaging reporter probe (D-Luciferin). This interaction is a chemiluminescent reaction that catalyzes the transformation of the substrate D-Luciferin into oxyluciferin in a process dependent on ATP, Mg++, and O2, leading to the emission of light, which can be detected by using low-light sensing instruments. Other gene/substrate combinations may be used as well (eg, hRluc and its substrate CL, see text). B, Bioluminescence neuroimaging in mice. Balb/c mice with 105 intracranially injected N2a cells transfected 24 hours previously with CMV-hRluc (right) and CMV-Fluc (left). Intracranial injections were performed immediately before substrate administration. The mice received intraperitoneal injections of the substrates D-Luciferin (1.5 mg) or CL (5µg) respectively. The charge-coupled device camera images were taken approximately 5–7 minutes post-substrate injections. Maximum signal intensity detected in photons per second per square centimeter per steradian is the following: Fluc, 2.1 x 106; hRluc, 9.2 x 104. CMV indicates cytomegalovirus; CMV-FL, adenoviral vector containing an imaging cassette with the CMV promoter driving the transcription of firefly luciferase gene.


Figure 2
View larger version (50K):
[in this window]
[in a new window]

 
Fig 2. The Xenogen In Vivo Imaging System (Xenogen Corporation, Hopkinton, Mass) consists of a cooled CCD camera mounted on a light-tight imaging chamber, a cryogenic refrigeration unit, a camera controller, and a computer system for data analysis